An integrated model for the glucose-insulin system

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 189-194

  Silber, Hanna E ^a,b   Jauslin, Petra M ^c   Frey, Nicolas ^c   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOKINASE; GLUCOSE; INSULIN;

COMPUTER SIMULATION; CONFERENCE PAPER; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; FEEDBACK SYSTEM; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INSULIN MODEL; HUMAN; INSULIN RELEASE; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROVOCATION TEST;

BLOOD GLUCOSE; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MODELS, BIOLOGICAL;

EID: 77149144465     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00510.x     Document Type: Conference Paper

References (31)

1. Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson USH, Karlsson MO. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol 2007 47 : 1159 1171.
2. Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K et al. An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol 2007 47 : 1244 1255.
3. Silber HE, Frey N, Karlsson MO. An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol. doi :.
4. Overgaard RV, Jelic K, Karlsson M, Henriksen JE, Madsen H. Mathematical beta cell model for insulin secretion following IVGTT and OGTT. Ann Biomed Eng 2006 34 : 1343 1354.
5. Panunzi S, Palumbo P, De Gaetano A. A discrete single delay model for the intra-venous glucose tolerance test. Theor Biol Med Mod 2007 4 : 35.
6. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979 236 : E667 77.
7. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guides. Icon Development Solutions, Ellicott City, Maryland, USA, 1989-2006.
8. Caumo A, Giacca A, Morgese M, Pozza G, Micossi P, Cobelli C. Minimal models of glucose disappearance: lessons from the labelled IVGTT. Diabet Med 1991 8 : 822 832.
9. Jauslin-Stetina P. Mechanism-based modeling of the glucose-insulin regulation during clinical provocation experiments. http://urn.kb.se/resolve? urn=urn:nbn:se:uu:diva-8719 (2009-02-19), 2008.
10. Dansirikul C, Karlsson MO. Insulin secretion and hepatic extraction during euglycemic clamp study: modelling of insulin and C-peptide data, PAGE 16, Abstr 1142, http://www.page-meeting.org/?abstract=1142, 2007.
11. Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G et al. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 2006 55 : 2001 2014.
12. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007 293 : E1 15.
13. Skelly AH. Type 2 diabetes mellitus. Nurs Clin North Am 2006 41 : 531 547, vi.
14. Unger J. Diagnosis and management of type 2 diabetes and prediabetes. Prim Care 2007 34 : 731 759, vi.
15. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS et al. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab 2005 90 : 352 358.
16. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992 340 : 925 929.
17. Taniguchi A, Nakai Y, Fukushima M, Kawamura H, Imura H, Nagata I et al. Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes 1992 41 : 1540 1546.
18. Fabietti PG, Canonico V, Orsini-Federici M, Sarti E, Massi-Benedetti M. Clinical validation of a new control-oriented model of insulin and glucose dynamics in subjects with type 1 diabetes. Diabetes Technol Ther 2007 9 : 327 338.
19. Sorensen JT, Colton CK, Hillman RS, Soeldner JS. Use of a physiologic pharmacokinetic model of glucose homeostasis for assessment of performance requirements for improved insulin therapies. Diabetes Care 1982 5 : 148 157.
20. Steil GM, Clark B, Kanderian S, Rebrin K. Modeling insulin action for development of a closed-loop artificial pancreas. Diabetes Technol Ther 2005 7 : 94 108.
21. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 2008 47 : 417 448.
22. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 2006 33 : 313 343.
23. Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 2003 55 : 147 157.
24. Ribbing J, Hamrén B, Svensson MK, Karlsson MO. Modelling the dynamics of glucose, insulin, insulin sensitivity and beta-cells in subjects with insulin resistance and patients with type 2 diabetes. PAGE 17, Abstr 1257, http://www.page-meeting.org/?abstract=1257, 2008.
25. Silber HE, Nyberg J, Hooker AC, Karlsson MO. Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design. J Pharmacokinet Pharmacodyn 2009 36 : 281 295.
26. Cobelli C, Ruggeri A. A reduced sampling schedule for estimating the parameters of the glucose minimal model from a labeled IVGTT. IEEE Trans Biomed Eng 1991 38 : 1023 1029.
27. Vicini P, Cobelli C. The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. Intravenous glucose tolerance test. Am J Physiol Endocrinol Metab 2001 280 : E179 86.
28. Bauer R, Guzy S, Silber HE, Jauslin PM, Frey N, Karlsson MO. Comparison between NONMEM and the Monte-Carlo Expectation Maximization (MC-PEM) Method using a physiologically-based glucose-insulin model. PAGE 16, Abstr 1214, http://www.page-meeting.org/?abstract=1214, 2007.
29. Hamren B, Bjork E, Sunzel M, Karlsson M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 2008 84 : 228 235.
30. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001 24 : 2023 2029.
31. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978 200 : 21 7.